The proceeds will be used to advance Augustine's lead candidate, AGT-100216, through a Phase I/II proof-of-concept clinical trial in CMT. Beyond AGT-100216, Augustine has two other programs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback